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Background
State-of-the-art medium and feed development has pro-
ven its potential for increasing bioprocess efficiency
many times. By the application of such advanced chemi-
cally defined and animal component-free formulations, in
combination with recent cell lines, the yield of mamma-
lian cell cultures was pushed to the binary gram per liter
level. In this work, the current progress in designing spe-
cial application media for transfection and single cell
growth is presented. In the context of medium develop-
ment, these techniques pose specific challenges which
differ from production media. However, interest in such
specialized products is high. On one side, clone selection
is a key factor for robust and effective processes. On the
other side, applications for transient transfection range
from purposes in R&D, over the production of pre-clini-
cal material to personalized medicine or vaccine produc-
tion. In terms of upscaling, efficient transient gene
expression (TGE) processes require a bifunctional med-
ium supporting both cell growth and transfection.
Material and methods
The work on a chemically defined and animal compo-
nent-free (ACF) medium for single cell growth was per-
formed in 96 well plates in comparison to serum
containing medium. Single cell growth was analyzed
using a Cellavista. A proof of concept for clone selection
was performed with different CHO cells including
upscaling from 96-well plates to shake flasks. Labile
recombinant protein expressed by isolated subclones
was quantified by ELISA and activity assay. For transient
transfection, the potential of the developed formulation
was demonstrated using various mammalian cell lines
(human and CHO). The transfection efficiency was eval-
uated using a polycationic transfection reagent and a
GFP expression plasmid. Additionally, the expression of
an IgG1 antibody was investigated for a HEK cell line
by batch, fed-batch and pseudo-perfusion performing
shaking flask cultivations after transient transfection in
fresh medium. Quantification of monoclonal antibody
titers was realized by protein A HPLC. The setup for
transfection varied in detail, but in general cells were
transfected at densities of 3·106 cells/mL using a polyca-
tionic transfection reagent. 2 pg DNA/cell were used in
transfections with plasmids harboring genes for the
expression of GFP or an IgG1. Culture volumes during
transfection ranged from 4 mL to 1000 mL.
Results
The performed proof of concept already illustrates the
capability of the current medium stage of the single cell
medium. Different single cells were successfully
expanded from 96 well plates, to 24 well plates, T-flasks
up to shaking flasks. The differences in final growth per-
formance and productivity of the selected clones exhib-
ited the heterogeneity within the original population
which was used for limited dilution. Regarding growth
performance in batch cultivation, the peak cell densities
of eight exemplary subclones ranged from 1.9·106 cells/
mL to 8.5·106 cells/mL. Product yield and activity of the
expressed labile protein varied by more than factor 3.
For the used development stage of the animal compo-
nent-free cloning medium, cloning efficiency was still
higher with serum addition. Nevertheless, the use of an
animal component-free cloning medium is advantageous
since the transfer to final ACF production medium is
significantly eased.
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Referring to transient transfection, the developed HEK
transfection medium supports stable cell growth in seed
train as well as high cell densities (up to 16·106 cells/mL)
and viability in batch cultivation. Using fresh medium at
the time of gene delivery, efficiencies in the range of68%
-94% for various HEK cell lines and 75% - 92% for one
evaluated CHO cell line were achieved (see Figure 1A). A
successful small scale pseudo-perfusion cultivation shows
the feasibility of this process strategy for transient gene
expression and is simply scaled-up to bioreactors. Such
perfusion processes are highly interesting for labile pro-
ducts, e.g. specific enzymes. Furthermore, monoclonal
antibody titers of 90 -150 mg/L were measured with a
commercially available reference medium that is recom-
mended for transient gene expression in such cell lines.
The application of our developed Xell medium resulted
in elevated titers of 310 - 430 mg/L, which is equivalent
with an increase by factor 3.1 on average. Design of
experiment (DOE) based optimization of the protocol
with addition of a specially tailored feed after transfection
further increased the yield to 750 - 850 mg/L. Compared
with the commercially available reference this is an
improvement by factor 6.7. An overview of these results
is illustrated in Figure 1B.
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Figure 1 Overview of transfection efficiency (A) achieved using the developed medium. Although designed for HEK cell lines, the medium
also supports high transfection rates for another human cell line as well as for CHO-K1. Furthermore, transient gene expression was evaluated by
monoclonal antibody yields (B). Results obtained using a well know commercially available medium recommended for TGE were compared to
titers achieved with the developed Xell medium.
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